These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
6. Toxicologic Pathology Forum*: Opinion on Designation of Adverse and Nonadverse Histopathological Findings in Toxicity Studies: The Pathologist's Dilemma. Gopinath C; Mowat V Toxicol Pathol; 2019 Jul; 47(5):564-573. PubMed ID: 31291835 [TBL] [Abstract][Full Text] [Related]
7. Considerations for the Identification and Conveyance of Clinical Pathology Findings in Preclinical Toxicity Studies: Results From the 9th ESTP International Expert Workshop. Arndt T; Keresztes M; Olivier B; Boone L; Chanut F; Ennulat D; Evans E; Freyberger A; Johannes S; Kuper CF; Maliver P; O'Brien P; Ramaiah L; Roman I; Strauss V; Vinken P; Walker D; Winter M; Pohlmeyer-Esch G; Tomlinson L Toxicol Pathol; 2024 Apr; ():1926233241245108. PubMed ID: 38661116 [TBL] [Abstract][Full Text] [Related]
8. Practical Considerations in Determining Adversity and the No-Observed-Adverse-Effect-Level (NOAEL) in Nonclinical Safety Studies: Challenges, Perspectives and Case Studies. Kale VP; Bebenek I; Ghantous H; Kapeghian J; Singh BP; Thomas LJ Int J Toxicol; 2022; 41(2):143-162. PubMed ID: 35230174 [TBL] [Abstract][Full Text] [Related]
9. Is It Adverse, Nonadverse, Adaptive, or Artifact? Pandiri AR; Kerlin RL; Mann PC; Everds NE; Sharma AK; Myers LP; Steinbach TJ Toxicol Pathol; 2017 Jan; 45(1):238-247. PubMed ID: 27770107 [TBL] [Abstract][Full Text] [Related]
10. A Brief Overview of the STP 35th Annual Symposium on the Basis and Relevance of Variation in Toxicologic Responses. Irizarry AR; Gropp KE; Dixon D Toxicol Pathol; 2017 Jan; 45(1):52-56. PubMed ID: 27815490 [TBL] [Abstract][Full Text] [Related]
11. Toxicology Paradise: Sorting Out Adverse and Non-adverse Findings in Animal Toxicity Studies. Baldrick P; Cosenza ME; Alapatt T; Bolon B; Rhodes M; Waterson I Int J Toxicol; 2020; 39(5):365-378. PubMed ID: 32618214 [TBL] [Abstract][Full Text] [Related]
12. Scientific and Regulatory Policy Committee Points to Consider*: Review of Scientific and Regulatory Policy Committee Points to Consider: Review of Current Practices for Ultrastructural Pathology Evaluations in Support of Nonclinical Toxicology Studies. Keirstead ND; Janovitz EB; Meehan JT; LeRoy BE; Megill JR; Peterson RA; Masson RG; Marxfeld HA Toxicol Pathol; 2019 Jun; 47(4):461-468. PubMed ID: 31018785 [TBL] [Abstract][Full Text] [Related]
13. Response letter from Clinical Pathology Interest Group of the Society of Toxicologic Pathology (STP) for manuscript entitled International recommendations for training future toxicologic pathologists participating in regulatory-type, nonclinical toxicity studies by Bolon et al. Tripathi NK; Schultze AE; Pearson RC; Everds NE; Elliott GS; Ramaiah L; Wells MY; Latimer KS; Walter GL; Katavolos P; Collins ND; Tarrant J; Walker DB; Topper MJ; Jordan HL; O'Rourke LG; Guilpin VB; Brockus CW; Wilcox AL; Clemo FA; Smith GS; Reagan WJ; McCartney JE Exp Toxicol Pathol; 2013 Jan; 65(1-2):39. PubMed ID: 21676604 [No Abstract] [Full Text] [Related]
14. The Application, Challenges, and Advancement Toward Regulatory Acceptance of Digital Toxicologic Pathology: Results of the 7th ESTP International Expert Workshop (September 20-21, 2019). Schumacher VL; Aeffner F; Barale-Thomas E; Botteron C; Carter J; Elies L; Engelhardt JA; Fant P; Forest T; Hall P; Hildebrand D; Klopfleisch R; Lucotte T; Marxfeld H; Mckinney L; Moulin P; Neyens E; Palazzi X; Piton A; Riccardi E; Roth DR; Rousselle S; Vidal JD; Williams B Toxicol Pathol; 2021 Jun; 49(4):720-737. PubMed ID: 33297858 [TBL] [Abstract][Full Text] [Related]
15. Scientific and Regulatory Policy Committee: Recommended ("Best") Practices for Determining, Communicating, and Using Adverse Effect Data from Nonclinical Studies. Kerlin R; Bolon B; Burkhardt J; Francke S; Greaves P; Meador V; Popp J Toxicol Pathol; 2016 Feb; 44(2):147-62. PubMed ID: 26704930 [TBL] [Abstract][Full Text] [Related]
16. International recommendations for training future toxicologic pathologists participating in regulatory-type, nonclinical toxicity studies. Bolon B; Barale-Thomas E; Bradley A; Ettlin RA; Franchi CA; George C; Giusti AM; Hall R; Jacobsen M; Konishi Y; Ledieu D; Morton D; Park JH; Scudamore CL; Tsuda H; Vijayasarathi SK; Wijnands MV Exp Toxicol Pathol; 2011 Jan; 63(1-2):187-95. PubMed ID: 20724123 [TBL] [Abstract][Full Text] [Related]
17. Is there a role for the no observed adverse effect level in safety pharmacology? Mow T; Andersen NK; Dragsted N; Lassen AB; Laursen M; Bass AS; Valentin JP; Markgraf C; Authier S; Baird TJ; Bhatt S; Traebert M; Leishman DJ; Jones D; Curtis MJ J Pharmacol Toxicol Methods; 2020 Sep; 105():106917. PubMed ID: 32866658 [TBL] [Abstract][Full Text] [Related]
18. Use of Severity Grades to Characterize Histopathologic Changes. Schafer KA; Eighmy J; Fikes JD; Halpern WG; Hukkanen RR; Long GG; Meseck EK; Patrick DJ; Thibodeau MS; Wood CE; Francke S Toxicol Pathol; 2018 Apr; 46(3):256-265. PubMed ID: 29529947 [TBL] [Abstract][Full Text] [Related]
19. Toxicologic Pathology Forum: Opinion on Approaches for Reporting Toxic and Adverse Dose Levels in Nonclinical Toxicology Studies Supporting the Development of Anticancer Pharmaceuticals. Hukkanen RR; Moriyama T; Patrick DJ; Werner J Toxicol Pathol; 2023 Jan; 51(1-2):81-86. PubMed ID: 36695335 [TBL] [Abstract][Full Text] [Related]
20. Publication Categories in Boyle MH; Bennet B; Colman K; Frisk AL; Garcia B; Houle CD; Romeike A; Sura R; Werner J; Elmore SA Toxicol Pathol; 2021 Jul; 49(5):1042-1047. PubMed ID: 33576326 [No Abstract] [Full Text] [Related] [Next] [New Search]